EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis

Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero Universitaria Careggi, University of Florence, Italy
Erasmus Medical Center, Rotterdam, the Netherlands
Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital, London, UK
No. 1 Hospital of Nanjing Medical University, China
ASST Grande Ospedale Metropolitano, Milano, Italy
Department of Hematology and Medical Oncology, University of Leipzig, Germany
Centre Hospitalier Universitaire d’Angers, France
Peking Union Medical College Hospital, Beijing, China
Novartis Pharma S.A.S, Rueil Malmaison, France
Novartis AG, Basel, Switzerland
Novartis AG, Basel, Switzerland
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
Vol. 104 No. 5 (2019): May, 2019